Bladder Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Bladder Cancer stocks.

Bladder Cancer Stocks Recent News

Date Stock Title
May 6 BCAB BioAtla announces FDA clearance of ind application for its treatment of multiple tumors
May 6 BCAB BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
May 5 URGN New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 4 URGN UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 4 URGN New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 3 URGN UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 2 NEO NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
May 2 BCAB BioAtla: A Buried ADC Concern Gets Some New Life In 2024
May 2 FUSN Fusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 2 NEO NeoGenomics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
May 1 AEZS Aeterna Zentaris Announces Effective Date of Share Consolidation
May 1 NEO NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...
Apr 30 NEO NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript
Apr 30 NEO Where NeoGenomics Stands With Analysts
Apr 30 NEO Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings
Apr 30 NEO NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows
Apr 30 NEO NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Apr 30 NEO NeoGenomics beats top-line and bottom-line estimates; reaffirms FY24 outlook
Apr 30 NEO NeoGenomics Reports First Quarter 2024 Results
Bladder Cancer

Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is a disease in which cells grow abnormally and have the potential to spread to other parts of the body. Symptoms include blood in the urine, pain with urination, and low back pain.Risk factors for bladder cancer include smoking, family history, prior radiation therapy, frequent bladder infections, and exposure to certain chemicals. The most common type is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma. Diagnosis is typically by cystoscopy with tissue biopsies. Staging of the cancer is typically determined by medical imaging such as CT scan and bone scan.Treatment depends on the stage of the cancer. It may include some combination of surgery, radiation therapy, chemotherapy, or immunotherapy. Surgical options may include transurethral resection, partial or complete removal of the bladder, or urinary diversion. Typical five-year survival rates in the United States are 77%.Bladder cancer, as of 2015, affects about 3.4 million people globally with 430,000 new cases a year. In 2015 it resulted in 188,000 deaths. Age of onset is most often between 65 and 85 years of age. Males are more often affected than females. In the United States in 2018 81,000 cases and 17,000 deaths are expected making it the 6th most common type of cancer in the region.

Browse All Tags